Skip to content
Open Imaging Index
MRI Brain

SHIVA cohort

RHU SHIVA cohort: stopping cognitive decline and dementia by fighting covert cerebral small vessel disease

Brain MRI and blood biomarkers of adults over 60 with extensive or minimal white matter lesions, collected to find markers of cerebral small vessel disease and predict cognitive decline. Ongoing French cohort, 150 enrolled by March 2024. Not public.

Go to dataset Edit Report

Overview

The SHIVA cohort is the clinical cohort of RHU SHIVA, a French research programme led from the University of Bordeaux and Bordeaux University Hospital that studies cerebral small vessel disease, a major cause of stroke and of cognitive decline. The cohort collects imaging and circulating biomarkers in older people with and without extensive small vessel disease, to build diagnostic and risk prediction tools. It is registered as NCT05306834 and started in November 2022. SHIVA-CMB (Tsuchida et al. 2024) used part of it as an unseen test set for microbleed segmentation.

Composition

Participants are over 60 and have either extensive white matter hyperintensities (Fazekas 2 or 3) or very few (Fazekas 0 or 1). The registry limits age to 60 to 88 and lists a cognitive complaint with MMSE of at least 20 and arterial hypertension among the inclusion criteria, except for extensive-disease patients enrolled from the LEOPOLD trial. As of March 2024, 150 participants had been enrolled; the registry gives a target of 400. The SHIVA-CMB test set holds 14 of them, 8 with extensive and 6 without extensive white matter hyperintensities.

Acquisition

MRI is done on 3 T Siemens Prisma scanners in Bordeaux and Paris and always includes a T2*-weighted gradient echo (TR 872 ms, TE 20 ms, flip angle 20 degrees, 1.0 x 1.0 x 2.5 mm). SWI is optional (TR 24 ms, TE 17.1 ms, flip angle 15 degrees, 0.8 x 0.8 x 3.0 mm). Other sequences and the clinical and blood data collected are not described in a public source found for this entry.

Annotations

For the 14 SHIVA-CMB test participants, two expert raters reviewed and corrected microbleed candidates proposed by an earlier version of the model, on both SWI and T2*-GRE. They report 112 microbleeds on SWI and 108 on T2*-GRE.

Known limitations

  • Not public. Requests go to the PI, no terms are published, and the trial registry states no plan to share individual data.
  • Recruitment is ongoing, so the counts here are a March 2024 snapshot.
  • Only the 14-participant microbleed test set is described in detail.

Cohort

Aggregate numbers from the sources below. Bars are relative to the 150 subjects.

Contrast / sequence

Groups can overlap

  • T2*-weighted 150 100%
  • Susceptibility-weighted 14 9%

Methods, Datasets, SHIVA in Tsuchida et al. 2024, SHIVA-CMB, Scientific Reports (PMC11680838)

Country

  • France 150 100%

Methods, Datasets, SHIVA in Tsuchida et al. 2024, SHIVA-CMB, Scientific Reports (PMC11680838)

Scanner vendor

  • Siemens Healthineers 150 100%

Methods, Datasets, SHIVA in Tsuchida et al. 2024, SHIVA-CMB, Scientific Reports (PMC11680838)

Field strength

  • 3 T 150 100%

Methods, Datasets, SHIVA in Tsuchida et al. 2024, SHIVA-CMB, Scientific Reports (PMC11680838)

License and access

Our reading of the license, not legal advice. Before you use the data, read the original license and confirm that your use is allowed. We take no responsibility for how you use a dataset. Full disclaimer

Access
On request

Ask the authors or the data holder. No published process or terms, and access is at their discretion

Access page

No published license or data use terms

The data holder has published no license and no data use terms. Any use, sharing or commercial right has to be agreed with the data holder, and nothing can be assumed to be allowed. Default copyright and data protection law still apply.

The SHIVA-CMB data availability statement says the cohort is not public because of French rules on sharing medical images, and that de-identified data may be available on request to the PI, Stéphanie Debette. The ClinicalTrials.gov record NCT05306834 states no plan to share individual participant data. No terms are published.

Original license text Checked 2026-10-08

What you can do

  • Commercial use Not stated
  • Not stated
  • Train ML models Not stated
  • Create derived data Not stated
  • Publish results Not stated

What you can share

  • Share the data Not stated
  • Share derived data Not stated
  • Share trained models Not stated

What you must do

  • Cite or credit Not stated
  • Share alike Not stated
  • Sign an agreement Not stated
  • Ethics approval Not stated
  • Manuscript review Not stated
  • Release code Not stated
  • Return results Not stated
  • Delete after use Not stated

Limits

  • No re-identification Not stated
  • Location limits Not stated

Citation

Tsuchida A, Goubet M, Boutinaud P, et al. SHIVA-CMB: a deep-learning-based robust cerebral microbleed segmentation tool trained on multi-source T2*GRE- and susceptibility-weighted MRI. Scientific Reports 14, 30901 (2024). doi:10.1038/s41598-024-81870-5

Sources

Every number on this page comes from one of these documents. Each chart names the table or page it is taken from. The raw numbers are in stats.csv.